Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer studynews2024-12-02T11:39:16+00:00December 2nd, 2024|Endpoints News|
Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plansnews2024-12-02T11:17:16+00:00December 2nd, 2024|Endpoints News|
Applied Therapeutics’ rare disease drug gets a CRLnews2024-11-27T22:15:08+00:00November 27th, 2024|Endpoints News|
Outlook’s shares crash as wet AMD drug flunks Phase 3 testnews2024-11-27T16:01:35+00:00November 27th, 2024|Endpoints News|
PTC reports Phase 2 ALS fail, sells priority review voucher for $150Mnews2024-11-27T13:35:17+00:00November 27th, 2024|Endpoints News|
Axsome moves toward NDA filing for narcolepsy drug after Phase 3 datanews2024-11-26T18:41:00+00:00November 26th, 2024|Endpoints News|
Food allergy biotech Alladapt closes after Phase 3 talks with FDAnews2024-11-26T16:04:03+00:00November 26th, 2024|Endpoints News|
Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readoutnews2024-11-26T12:34:29+00:00November 26th, 2024|Endpoints News|
Roche’s TIGIT drug misses overall survival endpoint in Phase 3 lung cancer trialnews2024-11-26T11:27:37+00:00November 26th, 2024|Endpoints News|
Alector says Alzheimer’s program targeting microglia fails Phase 2, stock divesnews2024-11-25T22:38:21+00:00November 25th, 2024|Endpoints News|
